News & Updates

Show Multimedia Only
Lenzilumab reduces likelihood of survival without ventilation in COVID-19 patients

Lenzilumab reduces likelihood of survival without ventilation in COVID-19 patients

14 Oct 2021 byAudrey Abella

In hospitalized COVID-19 patients, treatment with the novel GM-CSF* neutralizing monoclonal antibody lenzilumab led to a significant improvement in survival without invasive mechanical ventilation (SWOV), findings from the phase III LIVE-AIR study suggest.

Lenzilumab reduces likelihood of survival without ventilation in COVID-19 patients

14 Oct 2021
Wearable EMG detects poststroke muscle contractions in inactive patients

Wearable EMG detects poststroke muscle contractions in inactive patients

14 Oct 2021 byTristan Manalac

Wearable surface electromyograpghy (EMG) sensors can detect arm muscle activity in stroke survivors during standard acute care even if no such activity was observed during traditional clinical examination, according to a recent study.

Wearable EMG detects poststroke muscle contractions in inactive patients

14 Oct 2021
Climbing stairs boosts vascular function in patient with hypertension

Climbing stairs boosts vascular function in patient with hypertension

14 Oct 2021
Fatty pancreas carries increased risk of diabetes mellitus

Fatty pancreas carries increased risk of diabetes mellitus

14 Oct 2021
KEYNOTE unlocks immunotherapy OS benefit in metastatic TNBC, effective in early disease

KEYNOTE unlocks immunotherapy OS benefit in metastatic TNBC, effective in early disease

14 Oct 2021 byNatalia Reoutova

Triple-negative breast cancer (TNBC) is considered one of the highest-risk subtypes of breast cancer and has a dismal prognosis. However, immunotherapy survival benefits reported in KEYNOTE-522 and KEYNOTE-355 trials bring new hope for this indication. [Ann Oncol 2021;32:994-1004]

 

KEYNOTE unlocks immunotherapy OS benefit in metastatic TNBC, effective in early disease

14 Oct 2021
Common, cheap osteoporosis drug promising for T2D

Common, cheap osteoporosis drug promising for T2D

14 Oct 2021 byElvira Manzano

The osteoporosis drug alendronate halves the risk of developing type 2 diabetes (T2D) in a nationwide, retrospective, case-control study of nearly 700,000 patients from Denmark.

Common, cheap osteoporosis drug promising for T2D

14 Oct 2021
Dapagliflozin improves symptoms, physical limitations in HFpEF

Dapagliflozin improves symptoms, physical limitations in HFpEF

13 Oct 2021 byRoshini Claire Anthony

Patients with heart failure and preserved ejection fraction (HFpEF) treated with dapagliflozin experienced improvements in symptoms and physical limitations, according to results of the PRESERVED-HF study presented at HFSA 2021.

Dapagliflozin improves symptoms, physical limitations in HFpEF

13 Oct 2021
Tocilizumab cuts COVID-19 mortality when administered during the early inflammatory stage

Tocilizumab cuts COVID-19 mortality when administered during the early inflammatory stage

13 Oct 2021

Tocilizumab does not seem to prevent the progression of the coronavirus disease 2019 (COVID-19) to critical disease but may still be valuable in severely ill patients when used during the early inflammatory stages, a recent study has found.

Tocilizumab cuts COVID-19 mortality when administered during the early inflammatory stage

13 Oct 2021